{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T02:30:52Z","timestamp":1778898652802,"version":"3.51.4"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T00:00:00Z","timestamp":1563321600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T00:00:00Z","timestamp":1563321600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004844","name":"National Cheng Kung University Hospital","doi-asserted-by":"publisher","award":["10406030, 10505030, 10704006"],"award-info":[{"award-number":["10406030, 10505030, 10704006"]}],"id":[{"id":"10.13039\/501100004844","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12882-019-1452-5","type":"journal-article","created":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T13:02:38Z","timestamp":1563368558000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Serum sclerostin levels are positively related to bone mineral density in peritoneal dialysis patients: a cross-sectional study"],"prefix":"10.1186","volume":"20","author":[{"given":"Te-Hui","family":"Kuo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Hung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo-Yen","family":"Chao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An-Bang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chin-Chung","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Tzu","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hung-Hsiang","family":"Liou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Cheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,17]]},"reference":[{"key":"1452_CR1","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","volume":"69","author":"S Moe","year":"2006","unstructured":"Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G. Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2006;69:1945\u201353.","journal-title":"Kidney Int"},{"key":"1452_CR2","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1046\/j.1523-1755.1999.00617.x","volume":"56","author":"M Rix","year":"1999","unstructured":"Rix M, Andreassen H, Eskildsen P, Langdahl B, Olgaard K. Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int. 1999;56:1084\u201393.","journal-title":"Kidney Int"},{"key":"1452_CR3","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1053\/ajkd.2000.19812","volume":"36","author":"M Coco","year":"2000","unstructured":"Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis. 2000;36:1115\u201321.","journal-title":"Am J Kidney Dis"},{"key":"1452_CR4","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1053\/j.ajkd.2003.12.004","volume":"43","author":"J Cunningham","year":"2004","unstructured":"Cunningham J, Sprague SM, Cannata-Andia J, Coco M, Cohen-Solal M, Fitzpatrick L, Goltzmann D, Lafage-Proust MH, Leonard M, Ott S, et al. Osteoporosis in chronic kidney disease. Am J Kidney Dis. 2004;43:566\u201371.","journal-title":"Am J Kidney Dis"},{"key":"1452_CR5","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1172\/JCI28551","volume":"116","author":"V Krishnan","year":"2006","unstructured":"Krishnan V, Bryant HU, Macdougald OA. Regulation of bone mass by Wnt signaling. J Clin Invest. 2006;116:1202\u20139.","journal-title":"J Clin Invest"},{"key":"1452_CR6","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.cell.2006.10.018","volume":"127","author":"H Clevers","year":"2006","unstructured":"Clevers H. Wnt\/beta-catenin signaling in development and disease. Cell. 2006;127:469\u201380.","journal-title":"Cell."},{"key":"1452_CR7","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1097\/BOR.0b013e32816e06f9","volume":"19","author":"ML Johnson","year":"2007","unstructured":"Johnson ML, Kamel MA. The Wnt signaling pathway and bone metabolism. Curr Opin Rheumatol. 2007;19:376\u201382.","journal-title":"Curr Opin Rheumatol"},{"key":"1452_CR8","doi-asserted-by":"publisher","first-page":"877","DOI":"10.2215\/CJN.06550810","volume":"6","author":"D Cejka","year":"2011","unstructured":"Cejka D, Herberth J, Branscum AJ, Fardo DW, Monier-Faugere MC, Diarra D, Haas M, Malluche HH. Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol. 2011;6:877\u201382.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1452_CR9","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nm.3074","volume":"19","author":"R Baron","year":"2013","unstructured":"Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med. 2013;19:179\u201392.","journal-title":"Nat Med"},{"key":"1452_CR10","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1002\/jbmr.479","volume":"26","author":"MS Ardawi","year":"2011","unstructured":"Ardawi MS, Al-Kadi HA, Rouzi AA, Qari MH. Determinants of serum sclerostin in healthy pre- and postmenopausal women. J Bone Miner Res. 2011;26:2812\u201322.","journal-title":"J Bone Miner Res"},{"key":"1452_CR11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/jbmr.217","volume":"26","author":"UI Modder","year":"2011","unstructured":"Modder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Riggs BL, Melton LJ 3rd, Khosla S. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res. 2011;26:373\u20139.","journal-title":"J Bone Miner Res"},{"key":"1452_CR12","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1210\/jc.2011-2186","volume":"97","author":"A Garcia-Martin","year":"2012","unstructured":"Garcia-Martin A, Rozas-Moreno P, Reyes-Garcia R, Morales-Santana S, Garcia-Fontana B, Garcia-Salcedo JA, Munoz-Torres M. Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012;97:234\u201341.","journal-title":"J Clin Endocrinol Metab"},{"key":"1452_CR13","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s00198-010-1525-6","volume":"23","author":"SA Polyzos","year":"2012","unstructured":"Polyzos SA, Anastasilakis AD, Bratengeier C, Woloszczuk W, Papatheodorou A, Terpos E. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide. Osteoporos Int. 2012;23:1171\u20136.","journal-title":"Osteoporos Int"},{"key":"1452_CR14","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1530\/EJE-10-0699","volume":"163","author":"AH van Lierop","year":"2010","unstructured":"van Lierop AH, Witteveen JE, Hamdy NA, Papapoulos SE. Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls. Eur J Endocrinol. 2010;163:833\u20137.","journal-title":"Eur J Endocrinol"},{"key":"1452_CR15","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1038\/sj.ki.5001754","volume":"70","author":"M Jadoul","year":"2006","unstructured":"Jadoul M, Albert JM, Akiba T, Akizawa T, Arab L, Bragg-Gresham JL, Mason N, Prutz KG, Young EW, Pisoni RL. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis outcomes and practice patterns study. Kidney Int. 2006;70:1358\u201366.","journal-title":"Kidney Int"},{"key":"1452_CR16","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00198-014-2813-3","volume":"26","author":"RC Bucur","year":"2015","unstructured":"Bucur RC, Panjwani DD, Turner L, Rader T, West SL, Jamal SA. Low bone mineral density and fractures in stages 3-5 CKD: an updated systematic review and meta-analysis. Osteoporos Int. 2015;26:449\u201358.","journal-title":"Osteoporos Int"},{"key":"1452_CR17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","volume":"92","author":"M Ketteler","year":"2017","unstructured":"Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, Moe SM, Shroff R, Tonelli MA, Toussaint ND, et al. Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-MBD) guideline update: what's changed and why it matters. Kidney Int. 2017;92:26\u201336.","journal-title":"Kidney Int"},{"key":"1452_CR18","doi-asserted-by":"publisher","first-page":"819","DOI":"10.2215\/CJN.07670712","volume":"8","author":"S Pelletier","year":"2013","unstructured":"Pelletier S, Dubourg L, Carlier MC, Hadj-Aissa A, Fouque D. The relation between renal function and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol. 2013;8:819\u201323.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1452_CR19","doi-asserted-by":"publisher","first-page":"E1854","DOI":"10.1210\/jc.2014-2042","volume":"99","author":"M Kanbay","year":"2014","unstructured":"Kanbay M, Siriopol D, Saglam M, Kurt YG, Gok M, Cetinkaya H, Karaman M, Unal HU, Oguz Y, Sari S, et al. Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients. J Clin Endocrinol Metab. 2014;99:E1854\u201361.","journal-title":"J Clin Endocrinol Metab"},{"key":"1452_CR20","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00774-014-0639-x","volume":"33","author":"JJ Kazama","year":"2015","unstructured":"Kazama JJ, Matsuo K, Iwasaki Y, Fukagawa M. Chronic kidney disease and bone metabolism. J Bone Miner Metab. 2015;33:245\u201352.","journal-title":"J Bone Miner Metab"},{"key":"1452_CR21","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1093\/ndt\/gfr270","volume":"27","author":"D Cejka","year":"2012","unstructured":"Cejka D, Jager-Lansky A, Kieweg H, Weber M, Bieglmayer C, Haider DG, Diarra D, Patsch JM, Kainberger F, Bohle B, et al. Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Nephrol Dial Transplant. 2012;27:226\u201330.","journal-title":"Nephrol Dial Transplant"},{"key":"1452_CR22","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1007\/s00198-015-3127-9","volume":"26","author":"S Pelletier","year":"2015","unstructured":"Pelletier S, Confavreux CB, Haesebaert J, Guebre-Egziabher F, Bacchetta J, Carlier MC, Chardon L, Laville M, Chapurlat R, London GM, et al. Serum sclerostin: the missing link in the bone-vessel cross-talk in hemodialysis patients? Osteoporos Int. 2015;26:2165\u201374.","journal-title":"Osteoporos Int"},{"key":"1452_CR23","first-page":"656","volume":"16","author":"H Lee","year":"2011","unstructured":"Lee H, Hwang YH, Jung JY, Na KY, Kim HS, Son MJ, Park JY, Cho EJ, Ahn C, Oh KH. Comparison of vascular calcification scoring systems using plain radiographs to predict vascular stiffness in peritoneal dialysis patients. Nephrology (Carlton). 2011;16:656\u201362.","journal-title":"Nephrology (Carlton)"},{"key":"1452_CR24","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.jclinepi.2003.05.003","volume":"57","author":"KJ Ottenbacher","year":"2004","unstructured":"Ottenbacher KJ, Ottenbacher HR, Tooth L, Ostir GV. A review of two journals found that articles using multivariable logistic regression frequently did not report commonly recommended assumptions. J Clin Epidemiol. 2004;57:1147\u201352.","journal-title":"J Clin Epidemiol"},{"key":"1452_CR25","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.bone.2013.05.010","volume":"56","author":"G Hampson","year":"2013","unstructured":"Hampson G, Edwards S, Conroy S, Blake GM, Fogelman I, Frost ML. The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women. Bone. 2013;56:42\u20137.","journal-title":"Bone."},{"key":"1452_CR26","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00198-012-1978-x","volume":"24","author":"P Garnero","year":"2013","unstructured":"Garnero P, Sornay-Rendu E, Munoz F, Borel O, Chapurlat RD. Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study. Osteoporos Int. 2013;24:489\u201394.","journal-title":"Osteoporos Int"},{"key":"1452_CR27","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s00223-016-0160-4","volume":"99","author":"Y Lim","year":"2016","unstructured":"Lim Y, Kim CH, Lee SY, Kim H, Ahn SH, Lee SH, Koh JM, Rhee Y, Baek KH, Min YK, et al. Decreased plasma levels of Sclerostin but not Dickkopf-1 are associated with an increased prevalence of osteoporotic fracture and lower bone mineral density in postmenopausal Korean women. Calcif Tissue Int. 2016;99:350\u20139.","journal-title":"Calcif Tissue Int"},{"key":"1452_CR28","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s00223-012-9595-4","volume":"90","author":"S Thambiah","year":"2012","unstructured":"Thambiah S, Roplekar R, Manghat P, Fogelman I, Fraser WD, Goldsmith D, Hampson G. Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Calcif Tissue Int. 2012;90:473\u201380.","journal-title":"Calcif Tissue Int"},{"key":"1452_CR29","doi-asserted-by":"publisher","first-page":"4315","DOI":"10.1210\/jc.2014-2372","volume":"99","author":"E Ishimura","year":"2014","unstructured":"Ishimura E, Okuno S, Ichii M, Norimine K, Yamakawa T, Shoji S, Nishizawa Y, Inaba M. Relationship between serum sclerostin, bone metabolism markers, and bone mineral density in maintenance hemodialysis patients. J Clin Endocrinol Metab. 2014;99:4315\u201320.","journal-title":"J Clin Endocrinol Metab"},{"key":"1452_CR30","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375:1532\u201343.","journal-title":"N Engl J Med"},{"key":"1452_CR31","doi-asserted-by":"publisher","first-page":"3691","DOI":"10.1210\/jc.2011-3361","volume":"97","author":"MS Ardawi","year":"2012","unstructured":"Ardawi MS, Rouzi AA, Qari MH. Physical activity in relation to serum sclerostin, insulin-like growth factor-1, and bone turnover markers in healthy premenopausal women: a cross-sectional and a longitudinal study. J Clin Endocrinol Metab. 2012;97:3691\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"1452_CR32","doi-asserted-by":"publisher","first-page":"E1736","DOI":"10.1210\/jc.2012-1579","volume":"97","author":"JM Spatz","year":"2012","unstructured":"Spatz JM, Fields EE, Yu EW, Divieti Pajevic P, Bouxsein ML, Sibonga JD, Zwart SR, Smith SM. Serum sclerostin increases in healthy adult men during bed rest. J Clin Endocrinol Metab. 2012;97:E1736\u201340.","journal-title":"J Clin Endocrinol Metab"},{"key":"1452_CR33","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1093\/ndt\/gft039","volume":"28","author":"L Viaene","year":"2013","unstructured":"Viaene L, Behets GJ, Claes K, Meijers B, Blocki F, Brandenburg V, Evenepoel P, D'Haese PC. Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis? Nephrol Dial Transplant. 2013;28:3024\u201330.","journal-title":"Nephrol Dial Transplant"},{"key":"1452_CR34","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/nep.12509","volume":"20","author":"S Yamada","year":"2015","unstructured":"Yamada S, Tsuruya K, Tokumoto M, Yoshida H, Ooboshi H, Kitazono T. Factors associated with serum soluble inhibitors of Wnt-beta-catenin signaling (sclerostin and dickkopf-1) in patients undergoing peritoneal dialysis. Nephrology (Carlton). 2015;20:639\u201345.","journal-title":"Nephrology (Carlton)"},{"key":"1452_CR35","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1210\/jc.2009-2283","volume":"95","author":"FS Mirza","year":"2010","unstructured":"Mirza FS, Padhi ID, Raisz LG, Lorenzo JA. Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab. 2010;95:1991\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"1452_CR36","doi-asserted-by":"publisher","first-page":"689","DOI":"10.2217\/bmm-2016-0031","volume":"10","author":"S Jin","year":"2016","unstructured":"Jin S, Zhu M, Yan J, Fang Y, Lu R, Zhang W, Zhang Q, Lu J, Qi C, Shao X, et al. Serum sclerostin level might be a potential biomarker for arterial stiffness in prevalent hemodialysis patients. Biomark Med. 2016;10:689\u201399.","journal-title":"Biomark Med"},{"key":"1452_CR37","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003300","volume":"95","author":"BG Hsu","year":"2016","unstructured":"Hsu BG, Liou HH, Lee CJ, Chen YC, Ho GJ, Lee MC. Serum Sclerostin as an independent marker of peripheral arterial stiffness in renal transplantation recipients: a cross-sectional study. Medicine (Baltimore). 2016;95:e3300.","journal-title":"Medicine (Baltimore)"},{"key":"1452_CR38","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1080\/07435800.2017.1373662","volume":"43","author":"N Wang","year":"2018","unstructured":"Wang N, Xue P, Wu X, Ma J, Wang Y, Li Y. Role of sclerostin and dkk1 in bone remodeling in type 2 diabetic patients. Endocr Res. 2018;43:29\u201338.","journal-title":"Endocr Res"},{"key":"1452_CR39","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.bone.2013.08.016","volume":"57","author":"L Gifre","year":"2013","unstructured":"Gifre L, Ruiz-Gaspa S, Monegal A, Nomdedeu B, Filella X, Guanabens N, Peris P. Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover. Bone. 2013;57:272\u20136.","journal-title":"Bone."},{"key":"1452_CR40","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00223-008-9130-9","volume":"82","author":"W Balemans","year":"2008","unstructured":"Balemans W, Piters E, Cleiren E, Ai M, Van Wesenbeeck L, Warman ML, Van Hul W. The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations. Calcif Tissue Int. 2008;82:445\u201353.","journal-title":"Calcif Tissue Int"},{"key":"1452_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11505","volume":"7","author":"M Florio","year":"2016","unstructured":"Florio M, Gunasekaran K, Stolina M, Li X, Liu L, Tipton B, Salimi-Moosavi H, Asuncion FJ, Li C, Sun B, et al. A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair. Nat Commun. 2016;7:11505.","journal-title":"Nat Commun"},{"key":"1452_CR42","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/jbmr.2750","volume":"31","author":"T Isakova","year":"2016","unstructured":"Isakova T, Cai X, Lee J, Katz R, Cauley JA, Fried LF, Hoofnagle AN, Satterfield S, Harris TB, Shlipak MG, et al. Associations of FGF23 with change in bone mineral density and fracture risk in older individuals. J Bone Miner Res. 2016;31:742\u20138.","journal-title":"J Bone Miner Res"},{"key":"1452_CR43","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s00198-008-0780-2","volume":"20","author":"R Marsell","year":"2009","unstructured":"Marsell R, Mirza MA, Mallmin H, Karlsson M, Mellstrom D, Orwoll E, Ohlsson C, Jonsson KB, Ljunggren O, Larsson TE. Relation between fibroblast growth factor-23, body weight and bone mineral density in elderly men. Osteoporos Int. 2009;20:1167\u201373.","journal-title":"Osteoporos Int"},{"key":"1452_CR44","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.bone.2016.03.005","volume":"86","author":"EA Imel","year":"2016","unstructured":"Imel EA, Liu Z, McQueen AK, Acton D, Acton A, Padgett LR, Peacock M, Econs MJ. Serum fibroblast growth factor 23, serum iron and bone mineral density in premenopausal women. Bone. 2016;86:98\u2013105.","journal-title":"Bone."},{"key":"1452_CR45","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1007\/s00198-011-1838-0","volume":"23","author":"L Desjardins","year":"2012","unstructured":"Desjardins L, Liabeuf S, Renard C, Lenglet A, Lemke HD, Choukroun G, Drueke TB, Massy ZA. FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos Int. 2012;23:2017\u201325.","journal-title":"Osteoporos Int"},{"key":"1452_CR46","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/sj.ki.5002622","volume":"73","author":"P Urena Torres","year":"2008","unstructured":"Urena Torres P, Friedlander G, de Vernejoul MC, Silve C, Prie D. Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients. Kidney Int. 2008;73:102\u20137.","journal-title":"Kidney Int"},{"key":"1452_CR47","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1177\/0004563213515190","volume":"51","author":"TT Hlaing","year":"2014","unstructured":"Hlaing TT, Compston JE. Biochemical markers of bone turnover - uses and limitations. Ann Clin Biochem. 2014;51:189\u2013202.","journal-title":"Ann Clin Biochem"},{"key":"1452_CR48","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00198-004-1712-4","volume":"16","author":"S Okuno","year":"2005","unstructured":"Okuno S, Inaba M, Kitatani K, Ishimura E, Yamakawa T, Nishizawa Y. Serum levels of C-terminal telopeptide of type I collagen: a useful new marker of cortical bone loss in hemodialysis patients. Osteoporos Int. 2005;16:501\u20139.","journal-title":"Osteoporos Int"},{"key":"1452_CR49","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/089686080402400207","volume":"24","author":"AL Negri","year":"2004","unstructured":"Negri AL, Barone R, Quiroga MA, Bravo M, Marino A, Fradinger E, Bogado CE, Zanchetta JR. Bone mineral density: serum markers of bone turnover and their relationships in peritoneal dialysis. Perit Dial Int. 2004;24:163\u20138.","journal-title":"Perit Dial Int"},{"key":"1452_CR50","doi-asserted-by":"publisher","first-page":"c112","DOI":"10.1159\/000081552","volume":"98","author":"H Reichel","year":"2004","unstructured":"Reichel H, Roth HJ, Schmidt-Gayk H. Evaluation of serum beta-carboxy-terminal cross-linking telopeptide of type I collagen as marker of bone resorption in chronic hemodialysis patients. Nephron Clinical practice. 2004;98:c112\u20138.","journal-title":"Nephron Clinical practice"},{"key":"1452_CR51","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s00198-004-1655-9","volume":"16","author":"T Tsuchida","year":"2005","unstructured":"Tsuchida T, Ishimura E, Miki T, Matsumoto N, Naka H, Jono S, Inaba M, Nishizawa Y. The clinical significance of serum osteocalcin and N-terminal propeptide of type I collagen in predialysis patients with chronic renal failure. Osteoporos Int. 2005;16:172\u20139.","journal-title":"Osteoporos Int"},{"issue":"Suppl 1","key":"1452_CR52","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1016\/j.bone.2009.03.663","volume":"45","author":"T Hamano","year":"2009","unstructured":"Hamano T, Tomida K, Mikami S, Matsui I, Fujii N, Imai E, Rakugi H, Isaka Y. Usefulness of bone resorption markers in hemodialysis patients. Bone. 2009;45(Suppl 1):S19\u201325.","journal-title":"Bone."},{"key":"1452_CR53","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/BF00582163","volume":"50","author":"PJ Drinka","year":"1992","unstructured":"Drinka PJ, DeSmet AA, Bauwens SF, Rogot A. The effect of overlying calcification on lumbar bone densitometry. Calcif Tissue Int. 1992;50:507\u201310.","journal-title":"Calcif Tissue Int"},{"key":"1452_CR54","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1385\/JCD:5:2:193","volume":"5","author":"DD Cherney","year":"2002","unstructured":"Cherney DD, Laymon MS, McNitt A, Yuly S. A study on the influence of calcified intervertebral disk and aorta in determining bone mineral density. J Clin Densitom. 2002;5:193\u20138.","journal-title":"J Clin Densitom"},{"key":"1452_CR55","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1093\/ndt\/gfm660","volume":"23","author":"ND Toussaint","year":"2008","unstructured":"Toussaint ND, Lau KK, Strauss BJ, Polkinghorne KR, Kerr PG. Associations between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease. Nephrol Dial Transplant. 2008;23:586\u201393.","journal-title":"Nephrol Dial Transplant"},{"key":"1452_CR56","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s007740300004","volume":"21","author":"Y Nanjo","year":"2003","unstructured":"Nanjo Y, Morio Y, Nagashima H, Hagino H, Teshima R. Correlation between bone mineral density and intervertebral disk degeneration in pre- and postmenopausal women. J Bone Miner Metab. 2003;21:22\u20137.","journal-title":"J Bone Miner Metab"},{"key":"1452_CR57","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1093\/ndt\/gfx282","volume":"33","author":"P Delanaye","year":"2018","unstructured":"Delanaye P, Paquot F, Bouquegneau A, Blocki F, Krzesinski JM, Evenepoel P, Pottel H, Cavalier E. Sclerostin and chronic kidney disease: the assay impacts what we (thought to) know. Nephrol Dial Transplant. 2018;33:1404\u201310.","journal-title":"Nephrol Dial Transplant"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1452-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-019-1452-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1452-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T23:08:02Z","timestamp":1594854482000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-019-1452-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,17]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1452"],"URL":"https:\/\/doi.org\/10.1186\/s12882-019-1452-5","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,17]]},"assertion":[{"value":"18 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in the study involving human participants were in accordance with the Ethics of Clinical Research, Declaration of Helsinki. This research protocol was approved by the Institutional Review Board, National Cheng Kung University Hospital (approval number: B-ER-103-279). Written informed consent was obtained from each participant.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"266"}}